These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 510850)
21. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer. Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074 [No Abstract] [Full Text] [Related]
22. Intensification of antitumor-immunity by protein-bound polysaccharide, EA6, derived from Flammulina velutipes (Curt. ex Fr.) Sing. combined with murine leukemia L1210 vaccine in animal experiments. Otagiri K; Ohkuma T; Ikekawa T; Tanaka S J Pharmacobiodyn; 1983 Feb; 6(2):96-104. PubMed ID: 6683307 [TBL] [Abstract][Full Text] [Related]
23. I-Ad antigen expression of pyran copolymer-induced peritoneal cells in tumor vaccine-primed mice and its association with the host antitumor response. Oh-hashi F; Kataoka T; Taniyama T Cancer Immunol Immunother; 1987; 24(1):57-63. PubMed ID: 3102063 [TBL] [Abstract][Full Text] [Related]
24. [Elimination of suppressor macrophages in tumor-bearing mice by 6-mercaptopurine and its therapeutic contribution]. Kataoka T Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):701-5. PubMed ID: 3963841 [TBL] [Abstract][Full Text] [Related]
25. Prevention and treatment of L1210 mouse leukemia by immunization with xenogenized tumor cells combined with immunostimulation by the P40 fraction of C. granulosum and chemotherapy. Relyveld EH; Bizzini B; Ben-Efraim S Int J Immunopharmacol; 1984; 6(5):445-50. PubMed ID: 6500782 [TBL] [Abstract][Full Text] [Related]
26. Experimental chemotherapy (L1210) with 5-aza-2'-deoxycytidine in combination with pyran copolymer (MVE-4), an immune adjuvant. Zaharko DS; Covey JM; Muneses CC J Natl Cancer Inst; 1985 Jun; 74(6):1319-24. PubMed ID: 2582176 [TBL] [Abstract][Full Text] [Related]
27. Experience gained in immunotherapy from the immunopharmacology of BCG leading to a second generation of systemic immunity adjuvants. Mathe G Comp Immunol Microbiol Infect Dis; 1980; 3(4):407-32. PubMed ID: 6451350 [No Abstract] [Full Text] [Related]
28. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Zagozdzon R; Gołab J; Stokłosa T; Giermasz A; Nowicka D; Feleszko W; Lasek W; Jakóbisiak M Int J Cancer; 1998 Aug; 77(5):720-7. PubMed ID: 9688305 [TBL] [Abstract][Full Text] [Related]
29. Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice. Lasek W; Sora M; Wańkowicz A; Jakóbisiak M Cancer Lett; 1995 Feb; 89(1):137-43. PubMed ID: 7882296 [TBL] [Abstract][Full Text] [Related]
30. Letter: Routes other than I.V. injection to mice for BCG administration in active immunotherapy of L1210 leukemia. Martin M; Bourut C; Halle-Pannenko O; Mathé Biomedicine; 1975 Oct; 23(8):339-40. PubMed ID: 1231929 [No Abstract] [Full Text] [Related]
31. Mitomycin C-augmented production of I-A antigen-positive macrophages in tumor vaccine-primed mice. Kataoka T; Yamamoto T; Honjo K; Murayama T Jpn J Cancer Res; 1986 Mar; 77(3):305-11. PubMed ID: 3009373 [TBL] [Abstract][Full Text] [Related]
32. Acceleration of allogeneic antitumor immunity with immune RNA in vitro and T-cell suppression by L1210 tumor bearer spleen cells. Miura T; Maekawa T; Kurashige S; Mitsuhashi S Cancer Res; 1981 Feb; 41(2):383-98. PubMed ID: 6160907 [TBL] [Abstract][Full Text] [Related]
33. Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A. Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y Cancer Res; 1977 Apr; 37(4):964-8. PubMed ID: 403001 [TBL] [Abstract][Full Text] [Related]
34. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice. Warzocha K; Robak T Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753 [TBL] [Abstract][Full Text] [Related]
35. Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine. Sharma BS; Balazs L; Jin A; Wang JC; Jolley WB; Robins RK Cancer Immunol Immunother; 1991; 33(2):109-14. PubMed ID: 2036658 [TBL] [Abstract][Full Text] [Related]
36. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors. Nitta K; Tanaka T; Takeuchi M Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657 [TBL] [Abstract][Full Text] [Related]
37. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia. McGovren JP Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690 [TBL] [Abstract][Full Text] [Related]
38. Levamisole synergizes experimental F4ac+ Escherichia coli oral vaccine in stimulating ileal Peyer's patch T cells in weaned pigs. Bozić F; Lacković G; Kovsca-Janjatović A; Smolec O; Valpotić I J Vet Pharmacol Ther; 2006 Jun; 29(3):199-204. PubMed ID: 16669864 [TBL] [Abstract][Full Text] [Related]
39. Tumor idiotype vaccines. VI. Synergistic anti-tumor effects with combined "internal image" anti-idiotypes and chemotherapy. Chen JJ; Saeki Y; Shi LF; Köhler H J Immunol; 1989 Aug; 143(3):1053-7. PubMed ID: 2745974 [TBL] [Abstract][Full Text] [Related]
40. Human monocyte-lymphocyte interaction and its enhancement by levamisole. Kazura JW; Negendank W; Guerry D; Schreiber AD Clin Exp Immunol; 1979 Feb; 35(2):258-68. PubMed ID: 312172 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]